Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Ramkrishna Forgings Ltd, Leela Palaces Hotels & Resorts Ltd, Narayana Hrudayalaya Ltd, Craftsman Automation Ltd are among the other stocks to see a surge in volumes on BSE today, 30 January 2026.
Aurobindo Pharma Ltd clocked volume of 5.81 lakh shares by 10:46 IST on BSE, a 53.98 times surge over two-week average daily volume of 10754 shares. The stock gained 2.13% to Rs.1,175.00. Volumes stood at 13339 shares in the last session.
Ramkrishna Forgings Ltd notched up volume of 4.2 lakh shares by 10:46 IST on BSE, a 28.34 fold spurt over two-week average daily volume of 14831 shares. The stock rose 2.07% to Rs.518.10. Volumes stood at 6978 shares in the last session.
Leela Palaces Hotels & Resorts Ltd witnessed volume of 14.11 lakh shares by 10:46 IST on BSE, a 27.8 times surge over two-week average daily volume of 50757 shares. The stock increased 1.29% to Rs.406.75. Volumes stood at 3.08 lakh shares in the last session.
Narayana Hrudayalaya Ltd registered volume of 2.13 lakh shares by 10:46 IST on BSE, a 9.06 fold spurt over two-week average daily volume of 23486 shares. The stock rose 1.79% to Rs.1,774.30. Volumes stood at 9677 shares in the last session.
Craftsman Automation Ltd registered volume of 21129 shares by 10:46 IST on BSE, a 8.13 fold spurt over two-week average daily volume of 2598 shares. The stock rose 0.55% to Rs.7,348.45. Volumes stood at 2893 shares in the last session.
Aurobindo Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 1187.9, up 3.24% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.5% on the day, quoting at 25293. The Sensex is at 82170.1, down 0.48%. Aurobindo Pharma Ltd has gained around 0.41% in last one month.
Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has gained around 4.67% in last one month and is currently quoting at 21564, up 0.46% on the day. The volume in the stock stood at 49.13 lakh shares today, compared to the daily average of 8.28 lakh shares in last one month.
The benchmark February futures contract for the stock is quoting at Rs 1187.9, up 3.04% on the day. Aurobindo Pharma Ltd is up 1.37% in last one year as compared to a 7.59% jump in NIFTY and a 1.05% jump in the Nifty Pharma index.
The PE of the stock is 33.07 based on TTM earnings ending September 25.
Auto, metal and PSU bank shares advanced while FMCG, pharma shares declined.
At 09:25 IST, the barometer index, the S&P BSE Sensex advanced 161 points or 0.17% to 85,324.57. The Nifty 50 index added 51.65 points or 0.20% to 26,198.20.
In the broader market, the S&P BSE Mid-Cap index jumped 0.23% and the S&P BSE Small-Cap index gained 0.18%.
The market breadth was strong. On the BSE, 1,819 shares rose and 1,076 shares fell. A total of 156 shares were unchanged.
Foreign portfolio investors (FPIs) sold shares worth Rs 3,268.60 crore, while domestic institutional investors (DIIs) were net buyers to the tune of Rs 1,525.89 crore in the Indian equity market on 01 January 2026, provisional data showed.
Stocks in Spotlight:
RailTel Corporation of India rose 0.89%. The company has received a Letter of Acceptance (LoA) from the Assam Health Infrastructure Development & Management Society (AHIDMS) for procurement, implementation, and maintenance of a Hospital Management Information System (HMIS). The estimated order value is Rs 56.71 crore.
Aurobindo Pharma announced added 0.44%. The company that its subsidiary, Auro Pharma, has approved the acquisition of the non-oncology prescription formulations business of Khandelwal Laboratories on a going-concern basis through a Business Transfer Agreement for Rs 325 crore.
Time Technoplast added 2.66% after the company has received approvals from the Petroleum and Explosives Safety Organisation (PESO) and TÜV Rheinland (India) for the manufacture and supply of high-pressure Type-3 fully wrapped fiber-reinforced composite cylinders of 2-liter capacity for compressed gas applications.
Numbers to Track:
The yield on India's 10-year benchmark federal paper shed 0.03% to 6.579 as compared with the previous close of 6.581.
In the foreign exchange market, the rupee edged higher against the dollar. The partially convertible rupee was hovering at 89.9725 compared with its close of 89.9850 during the previous trading session.
MCX Gold futures for 5 February 2026 settlement rose 0.66% to Rs 136.704.
The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was down 0.16% to 98.17.
The United States 10-year bond yield rose 0.70% to 4.179.
In the commodities market, Brent crude for February 2025 settlement advanced 25 cents or 0.41% to $61.10 a barrel.
Global Markets:
South Korea’s Kospi hit a new record Friday as the Asia markets kicked off the new year on a positive trading note.
Some Asian markets were still closed for the holidays, including Japan and mainland China.
Meanwhile, Singapore’s economy expanded 5.7% year-on-year for the fourth quarter, driven mainly by strong manufacturing growth in the three months through December. The latest reading is faster than the revised 4.3% growth in the previous quarter.
On Wednesday, Prime Minister Lawrence Wong announced in his New Year message that the country had clocked a stronger-than-expected 4.8% expansion for the full year of 2025.
U.S. stock futures were looking up in early Asian hours, with S&P futures up by 0.15% and Nasdaq-100 futures climbing 0.12%. Dow Jones Industrial Average futures were 0.16% higher.
On Wednesday stateside, the S&P 500 dipped 0.74%, while the Nasdaq Composite fell 0.76% and the Dow Jones Industrial Average lost 0.63%.
The transaction was signed and completed on 1 January 2026. Under the agreement, Auro Pharma has acquired the branded non-oncology prescription formulations business of Khandelwal Laboratories as a going concern on a slump-sale basis. The acquisition includes inventory, intellectual property, employees, contracts, and other associated assets. The total cash consideration for the transaction is Rs 325 crore.
The acquisition is expected to strengthen the company’s pain management and anti-infective portfolio, complementing its existing offerings and supporting expansion in the domestic market.
Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services.
The company’s consolidated net profit increased 3.8% to Rs 848.45 crore on 7.7% increase in net sales to Rs 8,236.96 crore in Q2 FY26 over Q2 FY25.
Aurobindo Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 1198.8, down 0.61% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.36% on the day, quoting at 25948.55. The Sensex is at 84699.55, down 0.4%.Aurobindo Pharma Ltd has eased around 1.43% in last one month.Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has eased around 1.26% in last one month and is currently quoting at 22684.65, down 0.37% on the day. The volume in the stock stood at 2.55 lakh shares today, compared to the daily average of 6.38 lakh shares in last one month.
The benchmark December futures contract for the stock is quoting at Rs 1202.3, down 0.37% on the day. Aurobindo Pharma Ltd tumbled 7.66% in last one year as compared to a 9.74% rally in NIFTY and a 2.76% fall in the Nifty Pharma index.
The PE of the stock is 34.66 based on TTM earnings ending September 25.
At the end of the current inspection, a ‘Form 483' was issued with 05 observations which are procedural in nature, and we will respond to the US FDA within the stipulated timelines.
The scrip rose 0.36% to Rs 1,197.40 on the BSE.